Contact us: +91 9550333722 040 - 40102781
Structured search
India
Choose your country
Different countries will display different contents
Try our best to find the right business for you.
My chemicalbook

Welcome back!

HomecompanyMidecamycin Acetate
Midecamycin Acetate
Midecamycin Acetate

Midecamycin Acetate

Price USD17.00
Packge 1g
  • Min. Order:1g
  • Supply Ability:1KG
  • Time:2021-01-06

Product Details

  • Product NameMidecamycin Acetate
  • CAS No.55881-07-7
  • EINECS No.2598796
  • MFC45H71NO17
  • MW898.046
  • Melting point ~220° (with coloration)
  • Boiling point 878.7±65.0 °C(Predicted)
  • density 1.20±0.1 g/cm3(Predicted)
Midecamycin Acetate Basic information
Product Name: Midecamycin Acetate
Synonyms: Midecamycin Acetate;Leucomycin V, 3B,9-diacetate 3,4B-dipropanoate;3'',9-Diacetylmydecamycin;9,3''-Di-O-acetylmidecamycin;Acecamycin;Leucomycin V, 3B,9-diacetate 3,4B-dipropanoate (9CI);Miocamycin;Miokamycin
CAS: 55881-07-7
MF: C45H71NO17
MW: 898.046
EINECS: 259-879-6
Product Categories:  
Mol File: 55881-07-7.mol
Midecamycin Acetate Structure
 
Midecamycin Acetate Chemical Properties
Melting point  ~220° (with coloration)
alpha  D25 -53° (c = 1.0 in chloroform); D20 -74° (c = 1 in methanol)
Boiling point  878.7±65.0 °C(Predicted)
density  1.20±0.1 g/cm3(Predicted)
pka 13.06±0.70(Predicted)
 
Safety Information
MSDS Information
 
 
Midecamycin Acetate Usage And Synthesis
Description Miokamycin (midecamycin acetate) is a macrolide antibiotic useful in the treatment of respiratory tract, dermatological and surgical infections due to grampositive bacteria and mycoplasmas.
Originator Meiji Seika (Japan)
Brand name MIOCAMYCIN
Pharmaceutical Applications A semisynthetic diacetyl derivative of midecamycin A1. It is generally less active than erythromycin and some strains of H. influenzae and E. faecalis are resistant. It is rapidly and extensively metabolized, though some metabolites retain antibacterial activity.
Absorption of the dry formulation is unaffected by food, whereas that of the oral suspension is delayed. In various studies the peak plasma concentration was 1.65, 1.31–3 and 1.3–2.7 mg/L after doses of 400, 600 and 800 mg, respectively.
It is said to exhibit less toxicity than earlier macrolides. Attention has been paid to its interaction with theophylline, which resembles that of other macrolides. It is of limited availability.

Company Profile Introduction

Technology research and transfer of pilot screening, pilot scale-up and mass production solutions , for pharmaceutical intermediates, biologicals and fine chemicals (Not including inflammable , explosive , hazardous goods ) ; Market : Nano material , metal catalyst , raw material of cosmetics , pharmaceutical intermediates , chemicals , photoelectric material , import and export of technology and goods (For projects subject to approval according to law, business activities can be carried out only after approval by relevant departments ).
  • Since:2020-12-17
  • Address: Room 702, Floor 7, Building 10, National University Science Park, High-Tech Zone, Zhengzhou City, He
INQUIRY